Page 82 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Table 5. Monitoring criteria in protocols with curative intent in chronological order of starting enrollment year (continued)
Center, Country Monitoring Gleason # biopsy cores PSA Imaging Behavioral Additional Triggers for
[Pubmed ID] schedule score /% cores indication laboratory tests interventions
Enrollment years

Four tertiary Every 6-12 mo – – √ MRI of the – – Criteria for recommending
care academic PSA and DRE, prostate was treatment were
medical rebiopsies within selectively nonstandardized and
f
canters, US 109 18 mo and then every 1 to 3 yr physician specific.
[19233410] every 1 to 3 yr

1991-2007
UCSF, Every 3 mo PSA Gleason upgrade TRUS guided biopsy every PSA velocity – – – Disease progression; no
US 111,131-133,135 and DRE; prostate to ≥4 (if (≤6 at 6-12 mo >0.75 ng/mL/yr specific protocol for
[18433013; biopsy every 12- diagnosis) or intervention (implied)
21115873; 24 mo (after 2003) ≥4+3 (if 3+4 at ≥33% of cores or >50% of PSA DT < 1
21419438] diagnosis) 131 any core 132 yr 133

>1991 Rebiopsy ≥10 cores 135
Univ. of Every 3-4 mo PSA ≥7 110 >2 positive cores (After Biochemical TRUS (needed – – Treatment is encouraged
Miami, and DRE for 2 yr 2000, a peripherally progression: for determining at an increase in tumor
US 110,127 and every 6 mo targeted TRUS biopsy of PSA increase tumor volume) volume, Gleason score
[17850361; thereafter. 110 10-12 cores was performed 25-50 %/yr 127 110 ≥7, or the presence of >2
10759669] 9-12 mo after the first positive cores at
rebiopsy, and then annually rebiopsy. 110
1991-2007 or earlier if dramatic rise in Treatments were offered
PSA or a change on at the time of local stage
DRE.) 110 progression by DRE
and/or biochemical
progression, or systemic
progression. 127

42